YOLFTbeta
Adbiotech Co. Ltd.

Adbiotech Co. Ltd.

179530 · KQ · Healthcare / Biotechnology

728.00KRW-44.00 (-5.70%)

Price History

Full chart

Market Stats

Previous Close772.00
Open783.00
Day Range724.00 – 876.00
52-Week Range1,300.00 – 4,100.00
Volume922.55K
Market Cap48.70B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.23
50-Day Avg2,121.02
200-Day Avg2,189.53

About

ADBiotech Co., Ltd. develops and sells antibodies for livestock, fisheries, and humans in South Korea and internationally. The company offers antibiotic, disinfectant, helminthic, over the counter drugs, supplementary feed, and metabolic drugs. It also offers health functional and processed foods. ADBiotech Co., Ltd. was founded in 2000 and is based in Chuncheon-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Hong-Gul Cheong
  • Employees59
  • Headquarters39 Geodanji 1-gil, Chuncheon-si, South Korea, Korea
  • Websitehttps://adbiotech.com

Leadership

  • Mr. Hong-Gul CheongCEO & Director · b. 1962
  • Mr. KwangMyeong LeeVP & COO · b. 1977
  • Ms. EunJung JeongGM of Investment Management · b. 1992
  • Mr. KyungMin ChoiGM Business Management & Director · b. 1979

Financials

Income Statement

Currency: KRW2014-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue4.92B6.89B7.44B9.62B9.82B11.84B10.63B10.47B11.14B12.90B
Growth (%)-+40.02%+7.95%+29.34%+2.07%+20.63%-10.21%-1.50%+6.34%+15.81%
Cost of Revenue2.76B3.31B3.82B4.50B5.41B6.83B7.52B7.25B7.13B7.75B
Gross Profit2.15B3.58B3.62B5.12B4.41B5.01B3.11B3.22B4.01B5.15B
Gross Margin43.80%51.92%48.62%53.22%44.88%42.34%29.28%30.73%35.98%39.91%
Operating Expense3.46B3.30B6.88B4.86B5.40B6.64B8.05B10.60B8.68B8.65B
Operating Income-1.31B274.27M-3.27B254.72M-996.20M-1.63B-4.94B-7.38B-4.67B-3.50B
Operating Margin-26.53%3.98%-43.97%2.65%-10.15%-13.72%-46.45%-70.52%-41.96%-27.14%
EBITDA------3.55B-3.90B-7.31B-735.32M
EBITDA Margin------33.36%-37.22%-65.60%-5.70%
Net Income-787.01M283.05M-3.31B387.51M-7.34B-2.66B2.70B-2.86B-7.95B-3.30B
Net Income Margin-16.00%4.11%-44.52%4.03%-74.83%-22.50%25.36%-27.34%-71.41%-25.62%
R&D----788.46M550.16M1.11B1.49B1.63B1.80B
R&D as % of Total Revenue----8.03%4.65%10.45%14.19%14.66%13.97%
Interest Expense0000579.54M130.23M124.68M426.40M682.06M1.82B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%5.90%1.10%1.17%4.07%6.12%14.08%

Balance Sheet

Currency: KRW2014-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets9.97B10.45B9.70B11.36B18.84B20.96B31.02B28.09B23.07B48.41B
Total Liabilities6.82B5.85B5.18B4.37B9.51B15.85B14.83B17.25B18.24B34.87B
Total Equity3.15B4.60B4.53B6.99B9.33B5.11B16.19B13.39B4.84B15.32B
Cash286.60M563.16M1.34B1.31B2.44B1.20B1.18B3.01B638.53M3.91B
Total Debt6.00B3.93B3.52B2.32B5.77B-----
Net Debt----4.71B11.90B11.54B10.04B10.61B12.85B

Cash Flow

Currency: KRW2014-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-652.82M531.78M118.60M-74.54M-1.02B-2.16B-8.59B314.93M-4.09B-1.32B
Investing Cash Flow-580.70M481.68M-1.50B-474.36M-4.58B-4.52B-2.20B2.41B1.24B-
Financing Cash Flow724.87M-916.41M2.16B516.39M6.74B5.43B10.79B-885.19M484.41M-
Capital Expenditure514.94M2.29B2.39B94.47M5.29B3.56B726.72M289.90M193.38M377.68M
Free Cash Flow-----6.31B-5.72B-9.32B25.03M-4.29B-1.70B
FCF to OCF----618.89%264.74%108.46%7.95%104.73%128.64%

Earnings

Report DateMar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate------------------
EPS Actual-84.51-144.97-28.97377.06-24.43-43.86-103.62-141.37-464.45-203.16-118.97-83.40-38.22-444.15-382.92424.81-280.98-12.83
Surprise------------------
Timing------------------

Key Statistics & Ratios

Market Cap48.70B
Enterprise Value46.50B
Trailing P/E0.00
Forward P/E0.00
Price / Sales3.87
Price / Book1.67
Revenue (TTM)12.57B
Gross Profit (TTM)5.01B
EBITDA-3.48B
Profit Margin-28.07%
Operating Margin-66.65%
Return on Equity-23.55%
Return on Assets-7.20%
Shares Outstanding26.95M
Shares Float1.34M
Beta0.23
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • May 26, 20213:1